GNAS and cancer: Even though there has been a substantial advancement in the treatment of CRC using cytotoxic drugs, such as monoclonal antibodies to targeted therapy such as on the EGF receptor [49], the GNAS gene mutation is still regarded as a prominent contributor to treatment failure in cancer management and, hence, poor prognosis.